February 18th 2024
Despite socioeconomic and biological differences that contribute to disparities between Black men and White men with prostate cancer, improved access has been shown to reduce the gaps, explained Jun Gong, MD, of Cedars Sinai.
September 16th 2023
September 14th 2023
Study of South African Males With Prostate Cancer Reveals Limits of Current Germline Testing
March 10th 2023The findings, published in the Journal of the National Comprehensive Cancer Network, add to the evidence that the shift to precision medicine is built on data that have not included sufficient numbers of patients of color.
Read More
Study Characterizes Real-World Use of Relugolix in Combination With Other Prostate Cancer Therapies
February 19th 2023Relugolix was frequently used in combination with other medications for prostate cancer in patients both new to androgen-deprivation therapy and continuing androgen-deprivation therapy in a real-world study.
Read More
Hyaluronic Acid Spacer May Reduce Rectal Dosimetry, GI Toxicity From Prostate Cancer Treatment
February 9th 2023A randomized controlled trial found that the use of a rectal spacer may help mitigate the gastrointestinal (GI) toxicity associated with hypofractionated radiation therapy for prostate cancer.
Read More
Novel Assay Detects and Characterizes Even Microscopic Prostate Cancers
February 4th 2023A novel test developed at Cedars-Sinai Medical Center was able to detect and characterize even microscopic amounts of prostate cancers and could potentially help individualize treatment in the clinical setting.
Read More
International Panel Forms Consensus Best Practices for Active Surveillance in Prostate Cancer
February 1st 2023Health care expert and lived experience panels came to a consensus on several aspects that should be considered in the decision to offer and continue active surveillance for prostate cancer.
Read More
Risk Prediction for Risk Mitigation in Prostate Cancer Explored in New Study
January 14th 2023The importance of identifying rare pathogenic mutations and genetic risk score among patients was explored in this new analysis, with goals that included reducing mortality and early disease detection.
Read More
Social Determinants of Health Linked With Varying Prostate Cancer Outcomes by Race
January 13th 2023A meta-analysis supported that Black men have similar or better prostate cancer outcomes compared with White men when health care access is equal and treatment is standardized for all patients.
Read More
FDA Approves Darolutamide Combo for Metastatic Hormone-Sensitive Prostate Cancer
August 9th 2022Darolutamide, sold as Nubeqa, is an androgen receptor inhibitor, which works to limit prostate cell growth by preventing the binding of hormones, or androgens, to proteins known as androgen receptors.
Read More